Compare JetBlue Airways Corporation (JBLU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs TG Therapeutics Inc — how do they compare? JetBlue Airways Corporation trades at $5.8 (market cap $2.19B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 3.5× JetBlue Airways Corporation's market cap. Which is the better fit depends on your goals.
| JBLU | TGTX | |
|---|---|---|
Market Cap | $2.19B | $7.64B |
Sector | Industrials | Health |
52-Week High | $6.46 | $59.06 |
52-Week Low | $4.03 | $26.94 |
Enterprise Value | $9.56B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.855, up 3.81% today, with a bullish technical signal from moving averages but mixed earnings history including a recent Q2 2026 beat. The company shows negative profitability with a net income margin of -9.32% and ROE of -44.36%, while valuation ratios like P/S of 0.23 suggest potential undervaluation. Recent news highlights analyst downgrades and operational challenges from high fuel costs, alongside strategic initiatives like new fare structures and lounge awards.
Outlook remains cautious due to persistent losses and external pressures, but cost management and revenue growth initiatives offer recovery potential. Key risks include fuel price volatility and competitive intensity, while analyst consensus is neutral with a $5.18 price target slightly below current levels, indicating limited near-term upside amid ongoing fundamental headwinds.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
